Changes in List and Net Prices for Multiple Sclerosis Disease-Modifying Therapy, 2013 to 2021

20260 citationsJournal Articlegreen Open Access

Authors

Daniel M. Hartung · Oregon State University

Nico Gabriel · University of Montana

Walid F. Gellad · Pharmaceutical Formulations (United States)

Teresa Cameron · University of Montana

Noah Maxwell Feder · Pharmaceutical Formulations (United States)

Inmaculada Hernández · University of Montana

Abstract

The divergent net pricing trends between oral and MAb DMTs may reflect increasing brand and generic competition among oral DMTs and a lack of biosimilar options among MAb DMTs.

Topics & Keywords

Pharmaceutical Economics and Policy Biosimilars and Bioanalytical Methods Health Systems, Economic Evaluations, Quality of Life

Publication Details

Published in: Neurology Clinical Practice

Volume 16, Issue 2, pp. e200597-e200597

DOI: 10.1212/cpj.0000000000200597

Field-Weighted Citation Impact: 0.00

Command Palette

Changes in List and Net Prices for Multiple Sclerosis Disease-Modifying Therapy, 2013 to 2021

Authors

Abstract

Topics & Keywords

Publication Details